Available Structures

68 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal Structure of activated receptor tyrosine kinase in complex with substrates Heteromer
P10686;
464-770
DVT;ACP;MG;
Assess
Crystal structure of a monomeric human FGF9 in complex with the ectodomain of human FGFR1c Heteromer
P31371;
147-360
SO4;
Assess
Crystal Structure of FGF1 complexed with the ectodomain of FGFR1c exhibiting an ordered ligand spec… Heteromer
P05230;
147-359
SGN;
Assess
CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1… Heteromer
P05230;
147-359
SO4;
Assess
Crystal Structure of a 1:1:1 FGF23-FGFR1c-aKlotho Ternary Complex Heteromer
Q9GZV9; Q9UEF7;
149-361
NAG;ZN;
Assess
CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX Heteromer
P09038;
149-359
SO4;
Assess
CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX Heteromer
P09038;
149-359
SGN;SGN;
Assess
Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors Heteromer
Q8WU20;
409-430
Assess
Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazo…homo-2-mer458-765
SO4;EDO;2K7;
Assess
Crystal structure of minimal kinase domain of fibroblast growth factor receptor 1 in complex with 5…homo-2-mer459-765
VM1;PO4;
Assess
Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compou…homo-2-mer460-765
SO4; 10×EDO;0S9;
Assess
Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazo…homo-2-mer460-765
EDO;SO4;2K5;
Assess
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1homo-2-mer461-762
Assess
Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compou…homo-2-mer461-762
0S8;EDO;SO4;
Assess
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074homo-2-mer461-762
PD1;
Assess
Crystal structure of Human Fibroblast Growth Factor Receptor 1 Kinase domain in complex with compou…homo-2-mer461-762
0S7;EDO;
Assess
Crystal Structure of activated receptor tyrosine kinase in complex with substratesmonomer463-774
GQL;
Assess
Native FGFR1 with an inhibitormonomer458-765
CL;38O;
Assess
FGFR1 mutant with an inhibitormonomer458-764
38O;CL;
Assess
Crystal Structure of FGFR1 (C488A, C584S) in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETH…monomer458-764
66T;
Assess
Crystal structure of Fibroblast Growth Factor Receptor 1 kinase domainmonomer458-764
SO4;
Assess
Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M) in complex with N-{3-[2-…monomer458-764
66T;MG;
Assess
Crystal structure of FGFR1 kinase domain with Pemigatinibmonomer459-764
8ZF;SO4;
Assess
Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M), apomonomer460-764
Assess
Co-structure of Fibroblast Growth Factor Receptor 1 kinase domain with 3-(2,6-dichloro-3,5-dimethox…monomer461-765
07J;SO4;
Assess
Structure of the mutant Fibroblast Growth Factor receptor 1monomer461-765
Assess
Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 11.monomer462-765
SO4;EDO;O21;
Assess
Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to H3B-6527monomer463-765
9ES;SO4;EDO;
Assess
DISEASE LINKED MUTATION IN FGFRmonomer460-762
SO4;ACT;
Assess
FGFR1 in complex with dovitinibmonomer464-766
EDO;38O;SO4;
Assess
FGFR1 complex with N-(2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-3-methylph…monomer463-765
SO4;XL6;
Assess
FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693monomer464-765
SO4;5SF;
Assess
FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 38.monomer464-765
47I;SO4;EDO;
Assess
FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 34.monomer464-765
42I;SO4;EDO;
Assess
Crystal structure of FGFR1 kinase domain in complex with compound 3monomer464-765
AXU;
Assess
Crystal structure of FGFR1 kinase domain in complex with 7nmonomer464-765
4UT;
Assess
TAS-120 in reversible binding mode with FGFR1monomer464-765
TZ0;
Assess
FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3-methoxybenzyl)-7-azaindolemonomer464-765
C4F;
Assess
FGFR1 ligand complexmonomer464-765
SO4;EDO;XOJ;
Assess
FGFR1 kinase complex with inhibitor SN36985monomer464-765
YY7;SO4;
Assess
FGFR1 kinase domain complex with SN37333 in reversible binding modemonomer464-765
YY9;
Assess
TAS-120 covalent complex with FGFR1monomer464-765
TZ0;SO4;
Assess
FGFR1 kinase domain complexed with FIIN-1monomer464-765
MK9;SO4;
Assess
FGFR1 kinase domain complex with fragment 2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamidemonomer464-765
WP1;
Assess
Fibroblast growth factor receptor 1 kinase in complex with JK-P5monomer464-765
EDO;JVT;SO4;
Assess
Crystal structure of FGFR1-Y563C (FGFR4 surrogate) covalently bound to compound 22.monomer462-763
O1Y;SO4;
Assess
Structure of FGFR1 in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-…monomer465-765
66T;
Assess
FGFR1 kinase domain (residues 458-765) with mutations C488A, C584S in complex with 19.monomer465-765
466;SO4;EDO;CL;
Assess
Human FGF in complex with a covalent inhibitormonomer464-764
9K5;SO4;
Assess
Fibroblast growth factor receptor 1 kinase in complex with JK-P3monomer465-765
EDO;4Y0;PPI;SO4;
Assess
FGFR1 kinase complex with inhibitor SN37118monomer465-765
YY4;
Assess
Human FGF in complex with a covalent inhibitormonomer464-764
SO4;GOL;9K8;
Assess
Crystal structure of the catalytic domain of FGFR1 kinase in complex with ARQ 069monomer461-761
3RH;SO4;EDO;
Assess
FGFR1 kinase complex with inhibitor SN37116monomer465-765
YY6;
Assess
Crystal structure of FGFR1 (C488A, C584C) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-met…monomer465-765
Assess
FGFR1 kinase complex with inhibitor SN37115monomer465-765
YY5;SO4;
Assess
FGFR1 Apo structuremonomer462-762
PEG;CL;
Assess
Human FGFR1 kinase in complex with CH5183284monomer464-763
LWJ;SO4;
Assess
FGFR-1 in complex with ligand lenvatinibmonomer463-762
LEV;
Assess
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX W…monomer464-762
SU2;
Assess
Crystal structure of FGFR1 kinase domain in complex with a novel inhibitormonomer464-762
960;
Assess
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX W…monomer464-762
SU1;
Assess
Crystal structure of human fibroblast growth factor receptor 1 kinase domain in complex with pyrazo…monomer465-762
2M2;
Assess
Solution structure of the first Ig-like domain of human fibroblast growth factor receptor 1monomer38-123
Assess
cFMS tyrosine kinase in complex with 4-Cyano-1H-imidazole-2-carboxylic acid (2-cyclohex-1-enyl-4-pi…monomer577-597
ACT;KRJ;
Assess
cFMS Tyrosine kinase in complex with 5-Cyano-furan-2-carboxylic acid [4-(4-methyl-piperazin-1-yl)-2…monomer577-597
KRL;SO4;
Assess
cFMS tyrosine kinase in complex with a pyridopyrimidinone inhibitormonomer585-597
SO4;8C5;
Assess
Crystal structure of CSF1R kinase domain in complex with DP-6233monomer585-597
NA;CL;I9W;
Assess

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6v6q.1.Ahomo-2-mer0.77463-763
MG;81.45
Assess
1ry7.1.Bmonomer0.64152-361
58.23
Assess

53 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 26v6q.1.Ahomo-2-mer0.77461-761
MG;78.66
Assess
Isoform 21ry7.1.Bmonomer0.64152-361
58.41
Assess
Isoform 36v6q.1.Ahomo-2-mer0.77374-674
MG;81.45
Assess
Isoform 35w59.1.Bmonomer0.6958-271
99.11
Assess
Isoform 46v6q.1.Ahomo-2-mer0.77372-672
MG;78.66
Assess
Isoform 45w59.1.Bmonomer0.7158-271
99.11
Assess
Isoform 56v6q.1.Ahomo-2-mer0.78303-603
MG;81.25
Assess
Isoform 66v6q.1.Ahomo-2-mer0.78301-601
MG;78.66
Assess
Isoform 76v6q.1.Ahomo-2-mer0.77461-761
MG;81.45
Assess
Isoform 71ry7.1.Bmonomer0.65150-359
56.92
Assess
Isoform 73p3y.1.Amonomer0.5129-357
19.48
Assess
Isoform 85a46.1.Amonomer0.68464-646
88.52
Assess
Isoform 83b43.1.Amonomer0.5633-361
22.58
Assess
Isoform 85xwu.1.Cmonomer0.5432-359
22.42
Assess
Isoform 84pbx.1.Amonomer0.5436-360
22.94
Assess
Isoform 83p3y.1.Amonomer0.5029-359
19.09
Assess
Isoform 95a46.1.Amonomer0.68462-644
88.94
Assess
Isoform 93b43.1.Amonomer0.5533-361
22.58
Assess
Isoform 95xwu.1.Amonomer0.5532-360
22.34
Assess
Isoform 92yd9.1.Amonomer0.5232-357
22.94
Assess
Isoform 94pbx.1.Amonomer0.5236-361
22.86
Assess
Isoform 103ojm.1.Bmonomer0.7362-273
69.52
Assess
Isoform 101e0o.1.Bmonomer0.7162-270
78.67
Assess
Isoform 104j96.1.Amonomer0.70369-559
72.54
Assess
Isoform 105y32.1.Bmonomer0.5787-273
30.05
Assess
Isoform 113ojm.1.Bmonomer0.7462-272
69.86
Assess
Isoform 111e0o.1.Bmonomer0.7162-270
78.67
Assess
Isoform 114qqt.1.Amonomer0.69374-556
58.42
Assess
Isoform 115y32.1.Bmonomer0.5787-273
30.05
Assess
Isoform 123ojm.1.Bmonomer0.722-202
69.35
Assess
Isoform 124j96.1.Amonomer0.71298-489
71.65
Assess
Isoform 121e0o.1.Bmonomer0.691-199
79.10
Assess
Isoform 125y32.1.Bmonomer0.5716-202
30.05
Assess
Isoform 133ojm.1.Bmonomer0.723-201
69.54
Assess
Isoform 134j96.1.Amonomer0.71296-486
70.62
Assess
Isoform 131e0o.1.Bmonomer0.691-199
79.10
Assess
Isoform 135y32.1.Bmonomer0.5716-202
30.05
Assess
Isoform 146v6q.1.Ahomo-2-mer0.77372-672
MG;81.45
Assess
Isoform 143ojv.2.Bmonomer0.7058-268
99.55
Assess
Isoform 152ckn.1.Amonomer0.7135-119
94.12
Assess
Isoform 161cvs.1.Cmonomer0.7260-271
77.27
Assess
Isoform 163grw.1.Amonomer0.7063-270
53.92
Assess
Isoform 161e0o.1.Bmonomer0.7062-271
60.75
Assess
Isoform 172y8n.1.Bmonomer0.5831-57
37.04
Assess
Isoform 181cvs.1.Cmonomer0.7359-269
76.74
Assess
Isoform 183grw.1.Amonomer0.7161-268
53.92
Assess
Isoform 181e0o.1.Bmonomer0.7159-269
60.47
Assess
Isoform 196v6q.1.Ahomo-2-mer0.76463-763
MG;81.45
Assess
Isoform 191cvs.1.Cmonomer0.70151-358
88.69
Assess
Isoform 206v6q.1.Ahomo-2-mer0.77453-753
MG;78.66
Assess
Isoform 201ry7.1.Bmonomer0.65144-353
57.63
Assess
Isoform 216v6q.1.Ahomo-2-mer0.76494-794
MG;81.45
Assess
Isoform 211ry7.1.Bmonomer0.63183-395
62.63
Assess